Again, information and lower execution costs are where Insto's have an advantage over retail. In that former vein, just to let you know MACI got a feature in MSB's Bell Potter presentation when talking about its own degenerative disc disease treatment (I hate that they call it back pain - too unspecific). I believe the potential for chondrocytes in DDD well under-estimated, despite the known role of endplates degeneration (and tenocytes in the collagenous annulus fibrous):
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029037/
ACI has taken a back seat to CelGro and ATI - its only a small company with limited resources - but perhaps some future venture with Vericel not off the table. Orthocell actually compared themselves to Vericel quite a few years back:
Ann: Investor Presentation, page-46
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $78.49M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.5¢ | 36.5¢ | $32.14K | 86.68K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 65604 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 12.55pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
37.5¢ |
Change
0.005 ( 1.35 %) |
||||
| Open | High | Low | Volume | ||
| 37.0¢ | 38.0¢ | 37.0¢ | 21015 | ||
| Last updated 12.55pm 10/05/2024 ? | |||||
| OCC (ASX) Chart |